20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 12 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 16% bullish and 83%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $529,438, and 4 are calls, for a total amount of $126,443.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $660.0 to $1200.0 for Regeneron Pharmaceuticals over the recent three months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $660.0 to $1200.0 in the last 30 days.
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | SWEEP | BEARISH | 06/21/24 | $31.5 | $30.0 | $30.0 | $885.00 | $150.0K | 27 | 50 |
| REGN | PUT | SWEEP | NEUTRAL | 11/15/24 | $55.2 | $51.1 | $52.89 | $880.00 | $105.7K | 0 | 0 |
| REGN | PUT | SWEEP | NEUTRAL | 08/16/24 | $41.3 | $37.7 | $40.13 | $880.00 | $77.7K | 43 | 0 |
| REGN | PUT | TRADE | BEARISH | 05/17/24 | $54.1 | $52.2 | $54.1 | $950.00 | $54.1K | 41 | 0 |
| REGN | PUT | SWEEP | BEARISH | 04/26/24 | $19.0 | $19.0 | $19.0 | $910.00 | $39.9K | 2 | 26 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Where Is Regeneron Pharmaceuticals Standing Right Now?
- With a volume of 198,184, the price of REGN is down -1.73% at $920.0.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 21 days.
Expert Opinions on Regeneron Pharmaceuticals
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $1143.5.
- Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Regeneron Pharmaceuticals with a target price of $1135.
- An analyst from Truist Securities persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1135.
- An analyst from RBC Capital downgraded its action to Outperform with a price target of $1189.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1115.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with Benzinga Pro for real-time alerts.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!